Absolute Return Capital’s Theravance Biopharma TBPH Stock Holding History

Absolute Return Capital’s Portfolio TBPH Stock Details TBPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-23,701	Closed	-$260K	–	300
2015 Q3	$260K	Sell	23,701 -25,375	-52%	-$323K	0.02%	417
2015 Q2	$639K	Buy	49,076 +14,945	+44%	+$232K	0.03%	392
2015 Q1	$592K	Sell	34,131 -28,790	-46%	-$528K	0.02%	471
2014 Q4	$939K	Sell	62,921 -5,713	-8%	-$99.5K	0.02%	454
2014 Q3	$1.58M	Sell	68,634 -13,485	-16%	-$391K	0.02%	470
2014 Q2	$2.62M	Buy	+82,119	New	+$2.47M	0.03%	527

Other funds holding TBPH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

WIM

Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

RSCM

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Absolute Return Capital's TBPH Position: Q4 2015 in Review

Absolute Return Capital sold out of Theravance Biopharma (TBPH) in Q4 2015, closing a stake of 23,701 shares — an estimated $260K sold.

Absolute Return Capital first reported a position in TBPH in Q2 2014 and held it in 6 quarters. The position peaked at $2.62M in Q2 2014. 83 funds tracked by Wall St. Rank hold TBPH as of Q4 2015.

Absolute Return Capital reported no remaining Theravance Biopharma position as of Q4 2015 after selling out during the quarter.
Absolute Return Capital sold 23,701 Theravance Biopharma shares in Q4 2015, an estimated $260K.
Absolute Return Capital first reported a position in Theravance Biopharma in Q2 2014 and held it in 6 quarters.
Absolute Return Capital's Theravance Biopharma position peaked at $2.62M in Q2 2014.
83 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2015.

Based on Absolute Return Capital's 13F filing for Q4 2015.